NEO · Neogenomics Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | $413.04M | $370.47M | $347.04M | $321.83M | $297.27M | $258.56M |
| Gross Profit | $314.29M | $290.10M | $244.60M | $187.90M | $187.06M | $185.89M |
| R&D | $37.08M | $31.16M | $27.31M | $30.33M | $21.87M | $8.23M |
| SG&A | $273.34M | $259.74M | $243.10M | $243.36M | $221.35M | $143.79M |
| Total Operating Expenses | $430.17M | $382.21M | $352.34M | $345.52M | $305.81M | $199.88M |
| D&A | $36.07M | $39.10M | $37.45M | $35.37M | $30.19M | $25.90M |
| Operating Income | ($115.88M) | ($92.11M) | ($107.74M) | ($157.62M) | ($118.75M) | ($13.99M) |
| Interest Expense | $3.75M | $6.62M | $6.91M | $1.51M | $5.08M | $7.02M |
| Income Tax | ($2.24M) | ($1.95M) | ($9.13M) | ($15.09M) | ($6.73M) | ($18.23M) |
| Net Income | ($108.03M) | ($78.73M) | ($87.97M) | ($144.25M) | ($8.35M) | $4.17M |
| EPS - Basic | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $159.62M | $367.01M | $342.49M | $263.18M | $316.83M | $228.71M |
| Accounts Receivable | $159.24M | $150.54M | $131.23M | $119.71M | $112.13M | $106.84M |
| Inventory | $28.57M | $26.75M | $24.16M | $24.28M | $23.39M | $29.53M |
| Accounts Payable | $23.09M | $21.61M | $20.33M | $20.51M | $17.92M | $24.96M |
| Current Assets | $376.29M | $596.02M | $596.81M | $605.29M | $681.51M | $448.73M |
| Total Assets | $1.36B | $1.64B | $1.68B | $1.74B | $1.87B | $988.33M |
| Current Liabilities | $88.30M | $301.24M | $96.30M | $89.93M | $87.23M | $73.18M |
| Long-term Debt | $341.86M | $538.20M | - | - | - | - |
| Total Liabilities | $523.27M | $735.70M | $739.69M | $742.01M | $761.50M | $294.04M |
| Stockholders' Equity | $836.56M | $902.34M | $941.54M | $998.02M | $1.11B | $694.29M |
| Retained Earnings | ($433.81M) | ($325.78M) | ($247.06M) | ($159.09M) | ($14.84M) | ($7.18M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $5.23M | $7.02M | ($1.95M) | ($65.99M) | ($26.72M) | $1.46M |
| Investing Cash Flow | ($12.34M) | $12.86M | $76.71M | $517.0K | ($632.37M) | ($159.44M) |
| Financing Cash Flow | ($200.29M) | $4.65M | $4.55M | $11.83M | $725.28M | $235.60M |
| CapEx | $27.01M | $41.06M | $28.75M | $30.89M | $64.14M | $29.10M |
| Free Cash Flow | ($21.78M) | ($34.04M) | ($30.70M) | ($96.88M) | ($90.86M) | ($27.64M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.20 | 0.43 | 0.35 | 0.67 | 10.89 | -6.62 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -7.9% | -4.8% | -5.2% | -8.3% | -0.4% | 0.4% |
| Return on equity | -12.9% | -8.7% | -9.3% | -14.5% | -0.8% | 0.6% |
| Return on invested capital | -7.8% | -5.1% | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 4.26 | 1.98 | 6.20 | 6.73 | 7.81 | 6.13 |
| Quick ratio | 3.94 | 1.89 | 5.95 | 6.46 | 7.54 | 5.73 |
| Cash ratio | 1.81 | 1.22 | 3.56 | 2.93 | 3.63 | 3.13 |
| Leverage | ||||||
| Debt / Equity | 0.41 | 0.60 | - | - | - | - |
| Debt / Assets | 0.25 | 0.33 | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -30.9x | -13.9x | -15.6x | -104.7x | -23.4x | -2.0x |
| Equity multiplier | 1.63 | 1.82 | 1.79 | 1.74 | 1.69 | 1.42 |
| Liabilities / Assets | 0.38 | 0.45 | 0.44 | 0.43 | 0.41 | 0.30 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | 14.46 | 13.85 | 14.37 | 13.26 | 12.71 | 8.76 |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | 25d | 26d | 25d | 28d | 29d | 42d |
| Days payable outstanding | 20d | 21d | 21d | 23d | 22d | 35d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 1.8x | 2.3x | 2.2x | 1.2x | 3.7x | 8.7x |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | 486.1x |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | 8.3% | 18.6% | 30.2% | 0.4% | 0.6% | -5.6% |
| Operating income growth (YoY) | -25.8% | 14.5% | 31.6% | -32.7% | -748.7% | - |
| Net income growth (YoY) | -37.2% | 10.5% | 39.0% | -1628.2% | - | -47.9% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 36.0% | -10.9% | 68.3% | -6.6% | -228.8% | -1287.3% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -7.3% | -4.2% | -5.7% | -9.9% | 59.6% | 36.8% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Services-Testing Laboratories
Comparing NEOGENOMICS INC against the 4 most active filers in the same SIC group.